Neurology 2000;55:1748-1751
© 2000 American Academy of Neurology

A placebo-controlled crossover trial of creatine in mitochondrial diseases

T. Klopstock, MD,
V. Querner, MD, F. Schmidt,
F. Gekeler, MD, M. Walter, MD,
M. Hartard, MD,
M. Hennig Dipl-Stat,
T. Gasser, MD, D. Pongratz, MD,
A. Straube, MD,
M. Dieterich, MD and
W. MŸllerÐFelber, MD


From the Department of Neurology (Drs. Klopstock, Querner, Gekeler, Gasser, Straube, and Dieterich, and F. Schmidt) and the Friedrich-Baur-Institut (Drs. Walter, Pongratz, and MŸllerÐFelber), Ludwig-Maximilians-UniversitSt MŸnchen; and the Department of Sports Medicine (Dr. Hartard) and the Institute for Medical Statistics and Epidemiology (M. Hennig), Technische UniversitSt MŸnchen, Germany.

Address correspondence and reprint requests to Dr. Thomas Klopstock, Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-UniversitSt MŸnchen, D-81366 MŸnchen, Germany; e-mail: klopstock@brain.nefo.med.uni-muenchen.de

To test the efficacy and safety of creatine (Cr) monohydrate in mitochondrial diseases, 16 patients with chronic progressive external ophthalmoplegia or mitochondrial myopathy were randomized in a crossover design to receive double-blind placebo or 20 g Cr/day for 4 weeks. Cr was well tolerated, but there were no significant effects with regard to exercise performance, eye movements, or activities of daily life. The power of this pilot study was limited and future multicenter trials are needed.

Copyright © 2000 by AAN Enterprises, Inc.

Full text of article may be obtained, not free, at http://www.neurology.org/cgi/content/full/55/11/1748